Physician
Gastroenterology
Dr. Surinder K. Batra, MD
|
|
Give Review
Surinder Batra is an expert in the field of Gastroenterology. He went to medical school at Maulana Azad Medical College. He received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACG)". Surinder Batra is a published MD as well. He has 97 publications published. The latest was: Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus.
- PR55α subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling.
- Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.
- ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
- Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.
- Neuropilin-2 regulates endosome maturation and EGFR trafficking to support cancer cell pathobiology.
- Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
- Tumour exosome integrins determine organotropic metastasis.
- The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.
- Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.
- Codelivery of Small Molecule Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer.
- Genetically engineered mucin mouse models for inflammation and cancer.
- Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
- Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
- NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer.
- Mucins in lung Cancer: Diagnostic, Prognostic and Therapeutic Implications.
- Altered Mucins (MUC) Trafficking in Benign and Malignant Conditions.
- Insights into the Role of Nicotine in Pancreatic Stem Cell Activation and Acinar Dedifferentiation.
- Nano-immunoassay with improved performance for detection of cancer biomarkers.
- MUC16: molecular analysis and its functional implications in benign and malignant conditions.
- Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
- Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.
- Author's response to "Country of origin and breast cancer survival"
- Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages.
- A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation.
- PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia.
- Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.
- MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway.
- MicroRNAs (miRNA) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers.
- MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.
- Smoking and microRNA dysregulation: a cancerous combination.
- Molecular Biomarkers of Cancer Stem/Progenitor Cells Associated with Progression, Metastases and Treatment Resistance of Aggressive Cancers.
- Emerging Role of Mucins for Epithelial to Mesenchymal Transition.
- Introduction at the special issue on implications of cancer stem/progenitor cell concepts in molecular oncology and novel targeted therapies.
- Prospects of miRNA-Based Therapy for Pancreatic Cancer.
- Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.
- Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling.
- Emerging Trends for Radioimmunotherapy in Solid Tumors.
- Mucins in pancreatic cancer and its microenvironment.
- Cancer Stem Cells and Therapeutic Targets: An Emerging Field for Cancer Treatment.
- Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology.
- Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.
- Breast cancer survival of Hispanic women in the USA is influenced by country of origin.
- Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosi...
- Incidence and prognostic significance of second primary cancers in renal cell carcinoma.
- Holy Basil Leaf Extract Decreases Tumorigenicity and Metastasis of Aggressive Human Pancreatic Cancer Cells in vitro and in vivo: Potential Role in Therapy.
- Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer.
- Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through ?7nAChR-mediated MUC4 upregulation.
- MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells.
- Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer.
- Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.
- Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.
- Analysis of tumor-associated mucin glycotopes by Western transfer methods.
- Quantitative real-time PCR expression analysis of peripheral blood mononuclear cells in pancreatic cancer patients.
- Immunohistochemistry of pancreatic neoplasia.
- Pathobiological Implications of MUC4 in Non-Small-Cell Lung Cancer.
- Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.
- Targeting the EGFR signaling pathway in cancer therapy.
- Recent trends in antibody-based oncologic imaging.
- Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.
- Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.
- Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: Pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades ...
- MUC4 is a novel prognostic factor of oral squamous cell carcinoma.
- Frequent Gene Products and Molecular Pathways Altered in Prostate Cancer- and Metastasis-Initiating Cells and their Progenies and Novel Promising Multitargeted Therapies.
- MUC4 Stabilizes HER2 Expression and Maintains the Cancer Stem Cell Population in Ovarian Cancer Cells.
- Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering.
- Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.
- MUC17 protects intestinal epithelial cells from enteroinvasive E.coli infection by promoting epithelial barrier integrity.
- Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer.
- Human RNA Polymerase II-Association Factor 1 (hPaf1/PD2) Regulates Histone Methylation and Chromatin Remodeling in Pancreatic Cancer.
- Pathobiological Implications of MUC16 Expression in Pancreatic Cancer.
- Monoclonal Antibodies Recognizing the Non-Tandem Repeat Regions of the Human Mucin MUC4 in Pancreatic Cancer.
- Marital Status and Survival in Pancreatic Cancer Patients: A SEER Based Analysis.
- Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility.
- High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis.
- Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis.
- Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer.
- Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted ...
- Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
- Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.
- Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
- RNA polymerase II associated factor 1/PD2 maintains self-renewal by its interaction with Oct3/4 in mouse embryonic stem cells.
- Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells.
- Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.
- Characterization of nonmalignant and malignant prostatic stem/progenitor cells by Hoechst side population method.
- The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression.
- MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells.
- Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.
- Structure, evolution, and biology of the MUC4 mucin.
- Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.
- MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.
- Taurocholate-induced pancreatitis: a model of severe necrotizing pancreatitis in mice.
- Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.
- Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells.
- MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
- Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.
Schools
Maulana Azad Medical College Delhi University
Delhi University Hospital
Jewish Hospital
Henry Ford Hospital
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACG)
Education
-
Henry Ford Hospital - Wayne State University -
Maulana Azad Medical College
Hospital
-
Henry Ford Hospital
Drug Facts
| NPI NUMBER | 1083782510 | |
| NPPES Provider LastName | BATRA | |
| NPPES Provider FirstName | SURINDER | |
| NPPES Provider ZIPCode | 48202 | |
| NPPES Provider State | MI | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 160.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083782510 |
| Last Name Of The Provider | BATRA |
| First Name Of The Provider | SURINDER |
| View All |
Similar Doctors
|
Dr. Panapakkam Singaracharlu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary Ann Y. Huang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew J. Moeller, MD |
|
|
Dr. Mohammad R. Anees, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohamad Rasm Alsibae, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravindra N. Murthy, MD |
|
Dr. Krishnavel V. Chathadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hemal K. Patel, MD |
|
|
Dr. Reena J. Salgia, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sumit K. Singla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faisal Q. Khan, MD |
|
|
Dr. Charles E. Kelly, DO |